Physician profile
Abhash Joshi
NPI 1790098655
$2,906.49
in general payments reported to CMS, 2019-2025
23 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $95.20 · 2021: $476 · 2022: $308 · 2023: $477 · 2024: $747 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600 · Travel and Lodging: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.29 |
| Travel and Lodging | $301.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $777.99 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.54 | 2021-2024 | Ofev |
| Getinge USA Sales, LLC | $301.45 | 2025 | Vasoview Hemopro 2 |
| Abiomed | $267.93 | 2019-2024 | Impella |
| Glaxosmithkline, LLC. | $166.45 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $163.58 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| United Therapeutics Corporation | $155.00 | 2021-2023 | Tyvaso |
| Genzyme Corporation | $134.39 | 2022-2025 | |
| Electromed, INC. | $87.46 | 2023-2025 | Smartvest |
| Grifols USA, LLC | $77.36 | 2020-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Chiesi USA, INC. | $45.48 | 2022 | |
| Mylan Specialty L.P. | $37.81 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $24.76 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $21.38 | 2024 | Winrevair |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $20.71 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Ani Pharmaceuticals, INC. | $19.98 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $17.63 | 2025 | |
| Gilead Sciences, INC. | $17.59 | 2024 | |
| Verona Pharma, INC. | $17.12 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $16.83 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhash Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.